Your SlideShare is downloading. ×
0
Medidata Solutions
Earnings:
3 Things to Watch
Short-Term Investors
Wall Street
Expectations
Revenue
Q2: $81.9 million
Full Year: $341.1 million
Earnings per Share
Q2: $0.18
Full Year: $0.75...
•Before last quarter, Medidata’s earnings had exceeded
analyst expectations for five straight quarters. Over that
time fra...
Medium-Term Investors
Growing
Customer Base
Investors will be
watching to see if
more and more drug
companies use
Medidata to manage
drug develo...
•Medidata has consistently added to its customer base
by roughly 5% on a quarter-by-quarter basis.
•If the company can rea...
Long-Term Investors
Using multiple
products
The life sciences
industry is only so
big. Investors believe
Medidata can
continue growing
revenue...
•For most of the history of the company, Medidata’s
“Rave” cloud system has accounted for most of the
company’s revenue.
•...
Medidata Earnings: 3 Things This Shareholder Will Be Watching
Upcoming SlideShare
Loading in...5
×

Medidata Earnings: 3 Things This Shareholder Will Be Watching

1,340

Published on

Medidata Solutions offers cloud services to pharmaceutical companies. Can that lucrative niche continue to pay off for shareholders? Here's what to watch.

Published in: Economy & Finance
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
1,340
On Slideshare
0
From Embeds
0
Number of Embeds
13
Actions
Shares
0
Downloads
6
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

Transcript of "Medidata Earnings: 3 Things This Shareholder Will Be Watching"

  1. 1. Medidata Solutions Earnings: 3 Things to Watch
  2. 2. Short-Term Investors
  3. 3. Wall Street Expectations Revenue Q2: $81.9 million Full Year: $341.1 million Earnings per Share Q2: $0.18 Full Year: $0.75 Short-Term Investors
  4. 4. •Before last quarter, Medidata’s earnings had exceeded analyst expectations for five straight quarters. Over that time frame, the stock more than doubled. •However, when the company failed to meet expectations in April, the stock slipped as much as 30%. •Because it currently trades for 54 times trailing earnings, the stock will continue to move heavily based on how it performs versus Wall Street expectations. Short-Term Investors
  5. 5. Medium-Term Investors
  6. 6. Growing Customer Base Investors will be watching to see if more and more drug companies use Medidata to manage drug development logistics. Medium-Term Investors
  7. 7. •Medidata has consistently added to its customer base by roughly 5% on a quarter-by-quarter basis. •If the company can reach 440 total customers, investors will know that the company is still gaining traction with drug and life sciences companies. Medium-Term Investors
  8. 8. Long-Term Investors
  9. 9. Using multiple products The life sciences industry is only so big. Investors believe Medidata can continue growing revenues by offering add-on services. Long-Term Investors
  10. 10. •For most of the history of the company, Medidata’s “Rave” cloud system has accounted for most of the company’s revenue. •However, recently Medidata has started adding more add-on products that not only add value, but make switching costs very high for customers. •If Medidata can grow its percentage of customers using more than one product to 54%, that would be a great sign for investors. Long-Term Investors
  1. A particular slide catching your eye?

    Clipping is a handy way to collect important slides you want to go back to later.

×